β-O-甲基纤维二糖硫酸钠中和细胞外组蛋白对感染性休克的影响
该随机安慰剂对照实验在24只机械通气雌性羊中经粪性腹膜炎诱导脓毒症,分对照组、早期治疗组和晚期治疗组(每组8只)。mCBS按1 mg/kg负荷后1 mg/kg/h持续输注,早期组在脓毒症诱导后立即给药,晚期组在4小时后给药;液体复苏和抗菌治疗在注粪后4小时开始,并行腹腔灌洗,去甲肾上腺素滴定维持MAP 65-75 mmHg。早期治疗组前4小时MAP维持>65 mmHg,而其他组显著下降;mCBS治疗组去甲肾上腺素需求更少,肌酐、乳酸和IL-6水平更低,H3.1核小体变化减少;2只对照动物死亡,所有mCBS治疗动物存活。作者认为该策略可能代表一种新的治疗途径,有待临床试验验证。
要点
- 羊粪性腹膜炎感染性休克模型中,早期mCBS治疗组前4小时MAP维持>65 mmHg,晚期治疗组和对照组MAP显著下降(交互作用P<0.01;T4中位数:早期治疗组79 [70-90] mmHg,晚期治疗组57 [70-90] mmHg,对照组55 [49-60] mmHg)。
- mCBS治疗组维持MAP所需的去甲肾上腺素显著少于对照组(交互作用P<0.01),且早期治疗组去甲肾上腺素需求低于晚期治疗组。
- mCBS治疗组肌酐、乳酸和IL-6水平均显著低于对照组(P<0.01),H3.1核小体水平变化减少(P=0.02)。
- 2只对照动物死亡,所有mCBS治疗动物存活。
- 作者认为mCBS中和细胞外组蛋白可能代表一种新的感染性休克治疗途径,有待临床试验验证。
适用人群与场景
- 24只机械通气雌性羊,经粪性腹膜炎诱导脓毒症,随机分为对照组、早期治疗组和晚期治疗组(每组8只)。
- 实验在脓毒症诱导后4小时开始液体复苏和抗菌治疗,并行腹腔灌洗,去甲肾上腺素滴定维持MAP 65-75 mmHg,实验盲法持续最长24小时。
处置流程与药物剂量
- mCBS给药方案:负荷剂量1 mg/kg,随后持续输注1 mg/kg/h;早期治疗组在脓毒症诱导后立即给药,晚期治疗组在4小时后给药。
- 液体复苏和抗菌治疗在注粪后4小时开始,并执行腹腔灌洗;去甲肾上腺素输注滴定维持平均动脉压(MAP)在65-75 mmHg。
研究设计与关键结果
- 研究类型:随机安慰剂对照实验研究;样本量24只机械通气雌性羊;分组:对照组、早期治疗组、晚期治疗组(每组8只);脓毒症模型为粪性腹膜炎。
- 主要终点结果:前4小时MAP在早期治疗组维持>65 mmHg,其他组显著下降(交互作用P<0.01;T4中位数:早期治疗组79 [70-90] mmHg,晚期治疗组57 [70-90] mmHg,对照组55 [49-60] mmHg)。
- mCBS治疗组维持MAP所需去甲肾上腺素显著少于对照组(交互作用P<0.01),且早期治疗组去甲肾上腺素需求低于晚期治疗组。
- mCBS治疗组肌酐(P<0.01)、乳酸(P<0.01)和IL-6(P<0.01)水平低于对照组,H3.1核小体水平变化减少(P=0.02)。
- 生存:2只对照动物死亡,所有mCBS治疗动物存活。
证据类型、等级与局限
- 证据类型:随机安慰剂对照实验研究(动物实验)。
- 作者结论:mCBS中和细胞外组蛋白与去甲肾上腺素需求减少、组织灌注改善、肾功能障碍减轻和循环IL-6降低相关,可能代表一种新的治疗途径,有待临床试验验证。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,在实验性感染性休克中,mCBS中和细胞外组蛋白可能代表一种新的治疗途径,有待临床试验验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Extracellular histones have been associated with severity and outcome in sepsis. The aim of the present study was to assess the effects of sodium-β-O-Methyl cellobioside sulfate (mCBS), a histone-neutralizing polyanion, on the severity and outcome of sepsis in an experimental model.
METHODS: This randomized placebo-controlled experimental study was performed in 24 mechanically ventilated female sheep. Sepsis was induced by fecal peritonitis. Animals were randomized to three groups: control, early treatment, and late treatment (n = 8 each). mCBS was given as a bolus (1 mg/kg) followed by a continuous infusion (1 mg/kg/h) just after sepsis induction in the early treatment group, and 4 h later in the late treatment group. Fluid administration and antimicrobial therapy were initiated 4 h T4 after feces injection, peritoneal lavage performed, and a norepinephrine infusion titrated to maintain mean arterial pressure (MAP) between 65-75 mmHg. The experiment was blinded and lasted maximum 24 h.
RESULTS: During the first 4 h, MAP remained > 65 mmHg in the early treatment group but decreased significantly in the others (p < 0.01 for interaction, median value at T4: (79 [70-90] mmHg for early treatment, 57 [70-90] mmHg for late treatment, and 55 [49-60] mmHg for the control group). mCBS-treated animals required significantly less norepinephrine to maintain MAP than controls (p < 0.01 for interaction) and had lower creatinine (p < 0.01), lactate (p < 0.01), and interleukin-6 (p < 0.01) levels, associated with reduced changes in H3.1 nucleosome levels (p = 0.02). Early treatment was associated with lower norepinephrine requirements than later treatment. Two control animals died; all the mCBS-treated animals survived.
CONCLUSIONS: Neutralization of extracellular histones with mCBS was associated with reduced norepinephrine requirements, improved tissue perfusion, less renal dysfunction, and lower circulating IL-6 in experimental septic shock and may represent a new therapeutic approach to be tested in clinical trials.
参考来源
- Garcia B, Su F, Dewachter L, et al. Neutralization of extracellular histones by sodium-Β-O-methyl cellobioside sulfate in septic shock. Crit Care. 2023. PMID: 38001494. doi:10.1186/s13054-023-04741-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。